Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Studied

Randomized trial comparing liraglutide with placebo alongside standard care, tracking cardiovascular death, nonfatal heart attack or stroke.

Who / model

9340 people with type 2 diabetes and high cardiovascular risk; median follow-up was 3.8 years.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The primary combined cardiovascular outcome occurred in 13.0% versus 14.9%. Cardiovascular deaths were 4.7% versus 6.0%. Individual nonfatal heart attacks, strokes and heart-failure admissions did not show statistically clear differences. Digestive problems were the most common reason for stopping liraglutide.

Limits

Exploratory outcomes were tested without adjustment for making multiple comparisons.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary